Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Gegenanzeigen · Norvir
Norvir 100 mg powder for oral suspension · Abschnitt 4.3 · PDF-Seite 5
HOS-086159 · Präparat HOS-083284
Microsomal Lomitapide Increased plasma concentrations of lomitapide
triglyceride transfer (see section 4.5).
protein (MTTP)
inhibitor
PDE5 inhibitors Avanafil Increased plasma concentrations of avanafil
(see section 4.4. and 4.5).
Sildenafil Contraindicated when used for the treatment of
pulmonary arterial hypertension (PAH) only.
Increased plasma concentrations of sildenafil.
Thereby, increasing the potential for sildenafil-
associated adverse events (which include
hypotension and syncope). See section 4.4 and
section 4.5 for co-administration of sildenafil in
patients with erectile dysfunction.
Vardenafil Increased plasma concentrations of vardenafil
(see section 4.4. and 4.5).
Sedatives/hypnotics Clorazepate, diazepam, Increased plasma concentrations of clorazepate,
estazolam, flurazepam, diazepam, estazolam, flurazepam, oral
oral midazolam and midazolam and triazolam. Thereby, increasing
triazolam the risk of extreme sedation and respiratory
depression from these agents. (For caution on
parenterally administered midazolam, see
section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): estazolam (HOS-086165) lomitapide (HOS-086160) clorazepate (HOS-086164) diazepam (HOS-085904) avanafil (HOS-086161) sildenafil (HOS-086162) triazolam (HOS-086168) flurazepam (HOS-086166) midazolam (HOS-086167) vardenafil (HOS-086163)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 08cb4669d26fd4170f47a5f99fcf18bde7e922c35f378d07e3e1c1cab8b82945 · Zeichen 6375–8447 im Abschnitt
Gegenanzeigen · Norvir
Norvir 100 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 37
HOS-086390 · Präparat HOS-083284
Microsomal Lomitapide Increased plasma concentrations of lomitapide
triglyceride transfer (see section 4.5).
protein (MTTP)
inhibitor
PDE5 inhibitor Avanafil Increased plasma concentrations of avanafil
(see section 4.4. and 4.5).
Sildenafil Contraindicated when used for the treatment of
pulmonary arterial hypertension (PAH) only.
Increased plasma concentrations of sildenafil.
Thereby, increasing the potential for sildenafil-
associated adverse events (which include
hypotension and syncope). See section 4.4 and
section 4.5 for co-administration of sildenafil in
patients with erectile dysfunction.
Vardenafil Increased plasma concentrations of vardenafil
(see section 4.4. and 4.5).
Sedatives/hypnotics Clorazepate, diazepam, Increased plasma concentrations of clorazepate,
estazolam, flurazepam, diazepam, estazolam, flurazepam, oral
oral midazolam and midazolam and triazolam. Thereby, increasing
triazolam the risk of extreme sedation and respiratory
depression from these agents. (For caution on
parenterally administered midazolam, see
section 4.5.).
Ritonavir medicinal product level decreased
Herbal Preparation St. John’s Wort Herbal preparations containing St John’s wort
(Hypericum perforatum) due to the risk of
decreased plasma concentrations and reduced
clinical effects of ritonavir (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): estazolam (HOS-086165) lomitapide (HOS-086160) clorazepate (HOS-086164) diazepam (HOS-085904) avanafil (HOS-086161) sildenafil (HOS-086162) triazolam (HOS-086168) flurazepam (HOS-086166) midazolam (HOS-086167) vardenafil (HOS-086163)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-11T18:35:00Z · SHA-256 82413695e61cf39577e85c47e382ee60197570a4ae72fe81d6e24e4211cd2d43 · Passage 235db82cd2afd722d3066659d7d625c3a96a3162e89ca0b2b4a6f83e7ca9d95d · Zeichen 6173–8675 im Abschnitt
Gegenanzeigen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.3 · PDF-Seite 6
HOS-108817 · Präparat HOS-093083
HMG Co-A Reductase Lovastatin, simvastatin Increased plasma concentrations of
Inhibitors lovastatin and simvastatin; thereby,
increasing the risk of myopathy
including rhabdomyolysis (see section
4.5).
Microsomal Lomitapide Increased plasma concentrations of
triglyceride transfer lomitapide (see section 4.5).
protein (MTTP)
inhibitor
Phosphodiesterase Avanafil Increased plasma concentrations of
(PDE5) inhibitors avanafil (see sections 4.4 and 4.5).
Sildenafil Contraindicated when used for the
treatment of pulmonary arterial
hypertension (PAH) only. Increased
plasma concentrations of sildenafil.
Thereby, increasing the potential for
sildenafil-associated adverse events
(which include hypotension and
syncope). See section 4.4 and section
4.5 for co-administration of sildenafil in
patients with erectile dysfunction.
Vardenafil Increased plasma concentrations of
vardenafil (see sections 4.4 and 4.5)
Sedatives/hypnotics Oral midazolam, triazolam Increased plasma concentrations of oral
midazolam and triazolam. Thereby,
increasing the risk of extreme sedation
and respiratory depression from these
agents.
For caution on parenterally administered
midazolam, see section 4.5.
Lopinavir/ritonavir medicinal product level decreased
Herbal products St. John’s wort Herbal preparations containing St John’s
wort (Hypericum perforatum) due to the
risk of decreased plasma concentrations
and reduced clinical effects of lopinavir
and ritonavir (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lovastatin (HOS-086157) lomitapide (HOS-086160) simvastatin (HOS-086158) avanafil (HOS-086161) sildenafil (HOS-086162) triazolam (HOS-086168) midazolam (HOS-086167) vardenafil (HOS-086163)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage c938be9b188cbabde88400ddb49de67c2831b955f638dc8fa5306b13f1652968 · Zeichen 6187–9289 im Abschnitt
Gegenanzeigen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 43
HOS-108989 · Präparat HOS-093083
HMG Co-A Lovastatin, simvastatin Increased plasma concentrations of
Reductase Inhibitors lovastatin and simvastatin; thereby,
increasing the risk of myopathy
including rhabdomyolysis (see section
4.5).
Microsomal Lomitapide Increased plasma concentrations of
triglyceride transfer lomitapide (see section 4.5).
protein (MTTP)
inhibitor
Phosphodiesterase Avanafil Increased plasma concentrations of
(PDE5) inhibitors avanafil (see sections 4.4 and 4.5)
Sildenafil Contraindicated when used for the
treatment of pulmonary arterial
hypertension (PAH) only. Increased
plasma concentrations of sildenafil.
Thereby, increasing the potential for
sildenafil-associated adverse events
(which include hypotension and
syncope). See section 4.4 and section
4.5 for co-administration of sildenafil
in patients with erectile dysfunction.
Vardenafil Increased plasma concentrations of
vardenafil (see sections 4.4 and 4.5)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): lovastatin (HOS-086157) lomitapide (HOS-086160) simvastatin (HOS-086158) avanafil (HOS-086161) sildenafil (HOS-086162) vardenafil (HOS-086163)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage f8543c2c8cda6c1a0fcb441c8b738d361d39474d709f5eb46342c2fd917ec3a5 · Zeichen 6637–8576 im Abschnitt
Gegenanzeigen · Prezista
PREZISTA 100 mg/ml oral suspension · Abschnitt 4.3 · PDF-Seite 6
HOS-116288 · Präparat HOS-094447
Darunavir boosted with either ritonavir or cobicistat inhibits the elimination of active substances that
are highly dependent on CYP3A for clearance, which results in increased exposure to the
co-administered medicinal product. Therefore, concomitant treatment with such medicinal products
for which elevated plasma concentrations are associated with serious and/or life-threatening events is
contraindicated (applies to darunavir boosted with either ritonavir or cobicistat). These active
substances include e.g.:
- alfuzosin
- amiodarone, bepridil, dronedarone, ivabradine, quinidine, ranolazine
- astemizole, terfenadine
- colchicine when used in patients with renal and/or hepatic impairment (see section 4.5)
- ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine)
- elbasvir/grazoprevir
- cisapride
- dapoxetine
- domperidone
- naloxegol
- lurasidone, pimozide, quetiapine, sertindole (see section 4.5)
- triazolam, midazolam administered orally (for caution on parenterally administered midazolam,
see section 4.5)
- sildenafil - when used for the treatment of pulmonary arterial hypertension, avanafil
- simvastatin, lovastatin, lomitapide (see section 4.5)
- ticagrelor (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) ticagrelor (HOS-112065) quetiapine (HOS-086150) elbasvir (HOS-108814) alfuzosin (HOS-086139) methylergonovine (HOS-086155) dronedarone (HOS-086144) cisapride (HOS-085610) lovastatin (HOS-086157) lomitapide (HOS-086160) cobicistat (HOS-088111) bepridil (HOS-085612) simvastatin (HOS-086158) quinidine (HOS-085593) domperidone (HOS-114656) avanafil (HOS-086161) naloxegol (HOS-109428) grazoprevir (HOS-108815) ivabradine (HOS-109426) pimozide (HOS-085600) colchicine (HOS-086147) astemizole (HOS-085608) sildenafil (HOS-086162) ergotamine (HOS-086154) ritonavir (HOS-084521) amiodarone (HOS-085596) terfenadine (HOS-085607) lurasidone (HOS-086148) ranolazine (HOS-086141) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage e2536d703754b5f39bebb9603c70a8d8759f7198e0666cec1af181c80f42d82c · Zeichen 1442–2753 im Abschnitt
Gegenanzeigen · Prezista
PREZISTA 75 mg film-coated tablets PREZISTA 150 mg film-coated tablets PREZISTA 600 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 49
HOS-116497 · Präparat HOS-094447
Co-administration of PREZISTA with low dose ritonavir, with active substances that are highly
dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with
serious and/or life-threatening events. These active substances include e.g.:
- alfuzosin
- amiodarone, bepridil, dronedarone, ivabradine, quinidine, ranolazine
- astemizole, terfenadine
- colchicine when used in patients with renal and/or hepatic impairment (see section 4.5)
- ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine)
- elbasvir/grazoprevir
- cisapride
- dapoxetine
- domperidone
- naloxegol
- lurasidone, pimozide, quetiapine, sertindole (see section 4.5)
- triazolam, midazolam administered orally (for caution on parenterally administered midazolam,
see section 4.5)
- sildenafil - when used for the treatment of pulmonary arterial hypertension, avanafil
- simvastatin, lovastatin and lomitapide (see section 4.5)
- ticagrelor (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) ticagrelor (HOS-112065) quetiapine (HOS-086150) elbasvir (HOS-108814) alfuzosin (HOS-086139) methylergonovine (HOS-086155) dronedarone (HOS-086144) cisapride (HOS-085610) lovastatin (HOS-086157) lomitapide (HOS-086160) bepridil (HOS-085612) simvastatin (HOS-086158) quinidine (HOS-085593) domperidone (HOS-114656) avanafil (HOS-086161) naloxegol (HOS-109428) grazoprevir (HOS-108815) ivabradine (HOS-109426) pimozide (HOS-085600) colchicine (HOS-086147) astemizole (HOS-085608) sildenafil (HOS-086162) ergotamine (HOS-086154) ritonavir (HOS-084521) amiodarone (HOS-085596) terfenadine (HOS-085607) lurasidone (HOS-086148) ranolazine (HOS-086141) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 6a604bfa742092630f592a37246ad3ddd261ae7ceba904108fadd195ca4e43c8 · Zeichen 481–1534 im Abschnitt
Gegenanzeigen · Prezista
PREZISTA 400 mg film-coated tablets PREZISTA 800 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 87–88
HOS-116581 · Präparat HOS-094447
87
- dapoxetine
- domperidone
- naloxegol
- lurasidone, pimozide, quetiapine, sertindole (see section 4.5)
- triazolam, midazolam administered orally (for caution on parenterally administered midazolam,
see section 4.5)
- sildenafil - when used for the treatment of pulmonary arterial hypertension, avanafil
- simvastatin, lovastatin and lomitapide (see section 4.5)
- ticagrelor (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) ticagrelor (HOS-112065) quetiapine (HOS-086150) lovastatin (HOS-086157) lomitapide (HOS-086160) simvastatin (HOS-086158) domperidone (HOS-114656) avanafil (HOS-086161) naloxegol (HOS-109428) pimozide (HOS-085600) sildenafil (HOS-086162) lurasidone (HOS-086148) triazolam (HOS-086168) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2024-07-26T09:44:00Z · SHA-256 457dafbe8b3b9cee45b9ca7b46919ded598e0d0cd16715525d161e54f80b9117 · Passage 27a092d7005e5ab0411f0babdff280e728008e3766038685e07864d1fc35a1d1 · Zeichen 2308–2745 im Abschnitt
Gegenanzeigen · Genvoya
Genvoya 150 mg/150 mg/200 mg/10 mg film-coated tablets Genvoya 90 mg/90 mg/120 mg/6 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 4
HOS-133892 · Präparat HOS-097520
Co-administration with medicinal products that are highly dependent on CYP3A for clearance and for
which elevated plasma concentrations are associated with serious or life-threatening adverse reactions.
Therefore, Genvoya should not be co-administered with medicinal products that include, but are not
limited to, the following (see sections 4.4 and 4.5):
• alpha 1-adrenoreceptor antagonists: alfuzosin
• antiarrhythmics: amiodarone, quinidine
• ergot derivatives: dihydroergotamine, ergometrine, ergotamine
• gastrointestinal motility agents: cisapride
• HMG Co-A reductase inhibitors: lovastatin, simvastatin
• lipid-modifying agent: lomitapide
• neuroleptics/antipsychotics: pimozide, lurasidone
• PDE-5 inhibitors: sildenafil for the treatment of pulmonary arterial hypertension
• sedatives/hypnotics: orally administered midazolam, triazolam
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfuzosin (HOS-086139) cisapride (HOS-085610) lovastatin (HOS-086157) lomitapide (HOS-086160) simvastatin (HOS-086158) quinidine (HOS-085593) pimozide (HOS-085600) sildenafil (HOS-086162) ergotamine (HOS-086154) amiodarone (HOS-085596) lurasidone (HOS-086148) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-11-28T16:51:00Z · SHA-256 5b1a306ad5f7dd33700254558ee14691810f4eafdcf9d1256ccc229ad5e01997 · Passage 0f88e646d6d04d22e82ffc09fef77e923a5508a7e7714d22031d9defc05e872d · Zeichen 94–985 im Abschnitt
Wechselwirkungen · Genvoya
Genvoya 150 mg/150 mg/200 mg/10 mg film-coated tablets Genvoya 90 mg/90 mg/120 mg/6 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-133928 · Präparat HOS-097520
Co-administration of Genvoya and some medicinal products that are primarily metabolised by CYP3A
may result in increased plasma concentrations of these products, which are associated with the
potential for serious or life-threatening adverse reactions such as peripheral vasospasm or ischaemia
(e.g., dihydroergotamine, ergotamine, ergometrine), or myopathy, including rhabdomyolysis (e.g.,
simvastatin, lovastatin), or prolonged or increased sedation or respiratory depression (e.g., orally
administered midazolam or triazolam). Co-administration of Genvoya and other medicinal products
primarily metabolised by CYP3A such as amiodarone, lomitapide, quinidine, cisapride, pimozide,
lurasidone, alfuzosin and sildenafil for pulmonary arterial hypertension is contraindicated (see
section 4.3).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): alfuzosin (HOS-086139) cisapride (HOS-085610) lovastatin (HOS-086157) lomitapide (HOS-086160) simvastatin (HOS-086158) quinidine (HOS-085593) pimozide (HOS-085600) sildenafil (HOS-086162) ergotamine (HOS-086154) amiodarone (HOS-085596) lurasidone (HOS-086148) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-11-28T16:51:00Z · SHA-256 5b1a306ad5f7dd33700254558ee14691810f4eafdcf9d1256ccc229ad5e01997 · Passage 4dadcf172c034e4a296aebd72b2538a7bc83a7607f8e8d78e400d88f4a537379 · Zeichen 4154–4947 im Abschnitt
Wechselwirkungen · Genvoya
Genvoya 150 mg/150 mg/200 mg/10 mg film-coated tablets Genvoya 90 mg/90 mg/120 mg/6 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 19
HOS-134024 · Präparat HOS-097520
Lomitapide is highly dependent on
CYP3A for its metabolism and co-
administration with Genvoya may
result in increased concentrations
of lomitapide and potential for
markedly increased transaminases.
PHOSPHODIESTERASE TYPE 5 (PDE-5) INHIBITORS
Sildenafil Interaction not studied with any of Co-administration of Genvoya and
Tadalafil the components of Genvoya. sildenafil for the treatment of
Vardenafil pulmonary arterial hypertension is
PDE-5 inhibitors are primarily contraindicated.
metabolised by CYP3A.
Co-administration with Genvoya Caution should be exercised,
may result in increased plasma including consideration of dose
concentrations of sildenafil and reduction, when co-administering
tadalafil, which may result in Genvoya with tadalafil for the
PDE-5 inhibitor-associated adverse treatment of pulmonary arterial
reactions. hypertension.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tadalafil (HOS-086316) lomitapide (HOS-086160) sildenafil (HOS-086162) vardenafil (HOS-086163)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-11-28T16:51:00Z · SHA-256 5b1a306ad5f7dd33700254558ee14691810f4eafdcf9d1256ccc229ad5e01997 · Passage 2dafde215a518a5d94beacfbf46574f14f1047b5b936a19dfdf0d6a7eb00b4eb · Zeichen 43047–44522 im Abschnitt
Gegenanzeigen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 75 mg film-coated tablets Darunavir Viatris 150 mg film-coated tablets Darunavir Viatris 300 mg film-coated tablets Darunavir Viatris 600 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 5–6
HOS-134455 · Präparat HOS-097580
5
- triazolam, midazolam administered orally (for caution on parenterally administered midazolam,
see section 4.5)
- sildenafil - when used for the treatment of pulmonary arterial hypertension, avanafil
- simvastatin, lovastatin and lomitapide (see section 4.5)
- ticagrelor (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ticagrelor (HOS-112065) lovastatin (HOS-086157) lomitapide (HOS-086160) simvastatin (HOS-086158) avanafil (HOS-086161) sildenafil (HOS-086162) triazolam (HOS-086168) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 67ccf31dc842ed6550f68f2d93baf91e6520ae446833e0ce19545c6e63675c7e · Zeichen 1247–1563 im Abschnitt
Gegenanzeigen · Darunavir Viatris (previously Darunavir Mylan)
Darunavir Viatris 400 mg film-coated tablets Darunavir Viatris 800 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 44–45
HOS-134581 · Präparat HOS-097580
44
- cisapride
- dapoxetine
- domperidone
- naloxegol
- lurasidone, pimozide, quetiapine, sertindole (see section 4.5)
- triazolam, midazolam administered orally (for caution on parenterally administered midazolam,
see section 4.5)
- sildenafil - when used for the treatment of pulmonary arterial hypertension, avanafil
- simvastatin, lovastatin and lomitapide (see section 4.5)
- ticagrelor (see section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) ticagrelor (HOS-112065) quetiapine (HOS-086150) cisapride (HOS-085610) lovastatin (HOS-086157) lomitapide (HOS-086160) simvastatin (HOS-086158) domperidone (HOS-114656) avanafil (HOS-086161) naloxegol (HOS-109428) pimozide (HOS-085600) sildenafil (HOS-086162) lurasidone (HOS-086148) triazolam (HOS-086168) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-20T12:32:00Z · SHA-256 50f4771a683f17214737463c6df88a158b1e699bbb9916413602e547e369e804 · Passage 29477591ae9b5ad89ec5266de4b7dbb3559f802d26c18cc2d6b3cb9400a9440c · Zeichen 2288–2741 im Abschnitt
Gegenanzeigen · Symtuza
Symtuza 800 mg/150 mg/200 mg/10 mg film-coated tablets Symtuza 675 mg/150 mg/200 mg/10 mg film-coated tablets · Abschnitt 4.3 · PDF-Seite 4
HOS-138460 · Präparat HOS-098200
Co-administration with medicinal products such as those products listed below due to the potential for
serious and/or life-threatening adverse reactions (see section 4.5):
- alfuzosin
- amiodarone, dronedarone, ivabradine, quinidine, ranolazine
- colchicine when used in patients with renal and/or hepatic impairment (see section 4.5)
- rifampicin
- ergot derivatives (e.g. dihydroergotamine, ergometrine, ergotamine, methylergonovine)
- dapoxetine
- domperidone
- naloxegol
- pimozide, quetiapine, sertindole, lurasidone (see section 4.5)
- elbasvir/grazoprevir
- triazolam, midazolam administered orally (for caution on parenterally administered midazolam,
see section 4.5)
- sildenafil - when used for the treatment of pulmonary arterial hypertension, avanafil
- simvastatin, lovastatin and lomitapide (see section 4.5)
- ticagrelor
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertindole (HOS-085601) ticagrelor (HOS-112065) quetiapine (HOS-086150) elbasvir (HOS-108814) alfuzosin (HOS-086139) methylergonovine (HOS-086155) dronedarone (HOS-086144) lovastatin (HOS-086157) lomitapide (HOS-086160) simvastatin (HOS-086158) quinidine (HOS-085593) domperidone (HOS-114656) avanafil (HOS-086161) naloxegol (HOS-109428) grazoprevir (HOS-108815) ivabradine (HOS-109426) pimozide (HOS-085600) colchicine (HOS-086147) sildenafil (HOS-086162) ergotamine (HOS-086154) amiodarone (HOS-085596) lurasidone (HOS-086148) ranolazine (HOS-086141) triazolam (HOS-086168) dihydroergotamine (HOS-086152) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-16T11:21:00Z · SHA-256 542f840b29cc7afaff9940b20511550e8d35031b33d95efd774fd49f70f7819d · Passage d5339bf98a1f0c8c12e608ac2e03423cce35d78a9e0bb8d544d94fd38d39e9f0 · Zeichen 452–1349 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.